BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis-Reference-Cited by-同舟云学术

BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis

Published:2023-01-09 Issue:2 Volume:66 Page:1239-1253
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Huang Yahui¹,Liu Na¹^ORCID,Pan Zhizhi²,Li Zhuang¹,Sheng Chunquan¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, People’s Republic of China

2. College of Pharmacy, Dali University, Xueren Road 2, Dali 671000, People’s Republic of China

Funder

Shanghai Municipal Education Commission

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01191

Reference47 articles.

1. The antifungal pipeline: a reality check

2. How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future Directions

3. Antifungal Drugs: The Current Armamentarium and Development of New Agents

4. Systemic infection with Candida albicans in breast tumor bearing mice: Cytokines dysregulation and induction of regulatory T cells

5. Multidrug transporters of Candida species in clinical azole resistance

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of class I HDAC modulators: Inhibitors and degraders;European Journal of Medicinal Chemistry;2024-10

2. Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects;Journal of Medicinal Chemistry;2024-07-20

3. Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer;European Journal of Medicinal Chemistry;2024-04

4. Recent advances in multitarget-directed ligands via in silico drug discovery;Drug Discovery Today;2024-03

5. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis;European Journal of Medicinal Chemistry;2024-02